

24. Hrada K, Yoshida J, Mizuno M, Uozumi T. Growth inhibition of intra cerebral rat glioma by transfection-induced human interferon- $\beta$ . *J Surgical Oncology* 55, 105-109, 1995
25. Yoshida J, Mizuno M. Simple preparation and characterization of cationic liposomes associated with a monoclonal antibody against glioma-associated antigen (immunoliposomes). *J Liposome Res* 5, 981-995, 1995
26. Yoshida J, Mizuno M, Seo H, Ishikawa T, Kakumu S. Inhibition of hepatitis B virus replication by interferon- $\beta$  produced in situ by gene delivery. *Environ Med* 39, 33-36, 1995
27. Mizuno M, Yoshida J. Tumor necrosis factor- $\alpha$  gene transfer transfer augments anti-Fas antibody-mediated apoptosis in human glioma cells. *Jpn J Cancer Res* 8, 543-547, 1996
28. Mizuno M, Yoshida J. Repeated exposure to cationic immunoliposomes activates effective gene transfer to human glioma cells. *Neurologia Medico-Chirurgica* 36, 141-144, 1996
29. Sadatomo T, Yoshida J, Wakabayashi T, Mizuno M, Harada K, Kurisu K, Uozumi T, Sugita K. New approach for the treatment of medulloblastoma by transfection with glial fibrillary acidic protein gene. *Surgical Oncol* 5, 69-75, 1996
30. Okada H, Miyamura K, Itoh T, Hagiwara M, Wakabayashi T, Mizuno M, Colosi P, Kurtzman G, Yoshida J. Gene therapy against an experimental glioma using adeno-associated virus vectors. *Gene Therapy* 3, 957-964, 1996
31. Yoshida J, Takaoka T, Mizuno M, Momota H, Okada H. Cytolysis of malignant glioma cells by lymphokine-activated killer cells combined with anti-CD3 antiglioma bifunctional antibody and tumor necrosis factor- $\alpha$ . *J Surgical Oncol* 62, 177-182, 1996
32. Yoshida J, Wakabayashi T, Mizuno M, Takaoka T, Okamoto S, Okada H, Yagi K. Cytokine gene therapy of malignant glioma by means of DNA/liposomes. *Brain Tumor Research and Therapy*; Springer-Verlag (Tokyo) 1995.
33. Wakabayashi T, Yoshida J, Takaoka T, Sadamoto T, Mizuno M, kimura S. Enzyme immunoassay of glioma cell tenascin secretion and augmentation by tumor necrosis factor- $\alpha$ . *Neurologia Medico-Chirurgica* 37, 392-398, 1997
34. Ohta S, Mizuno M, Takaoka T, Yoshida J. Augmentation of anti-Fas antibody-mediated apoptosis on human glioma cells by liposomes associated with the antibody. *J Neuro-Oncology* 35, 7-11, 1997
35. Mizuno M, Yoshida J, Colosi P, Kurtzman GJ. Adeno-associated virus vector containing the herpes simplex virus-thymidine kinase gene cause complete regression of intracerebrally implanted human gliomas in mice. *Jpn J Cancer Res* 89, 76-80, 1998
56. Mizuno M, Yoshida J. Improvement of transduction efficiency of recombinant adeno-associated virus vector by entrapment in multilamellar liposomes. *Jpn J Cancer Res* 89, 352-354, 1998
37. Bucur N, Mizuno M, Wakabayashi T, Yoshida J. Growth inhibition of experimental glioma by human interferon- $\beta$  superinduced by cationic liposomes entrapping polyinosilic: polycytidilic acid. *Neurol Med Chir* 37, 763-771, 1998
38. Ohta S, Yoshida J, Yamamoto S, Uemura K, Wakabayashi T, Mizuno M, Sakurai T, Terakawa S. Video-enhanced microscopic visualization of apoptotic cell death caused by anti-

- Fas antibody in living human glioma cells. *Brain Tumor Pathol* 15, 19-21, 1998
39. Mizuno M, Yoshida J. Effect of human interferon- $\beta$  gene transfer upon human glioma transplanted into nude mouse brain involves induced natural killer cells. *Cancer Immunol Immunother* 47, 227-231, 1998
  40. Bouhon IA, Shinkai M, Honda H, Mizuno M, Wakabayashi T, Yoshida J, Kobayashi T. Synergism between mild hyperthermia and interferon- $\beta$  gene expression. *Cancer Letters* 139, 153-158, 1999
  41. Natsume A, Mizuno M, Ryuke Y and Yoshida J. Antitumor effect and cellular immunity activation by murine interferon- $\beta$  gene transfer against intracerebral glioma in mouse. *Gene Therapy* 6, 1626-1633, 1999
  42. Otsuka G, Nagaya T, Saito K, Mizuno M, Yoshida J, Seo H. Inhibition of NF- $\kappa$ B activation confers sensitivity to TNF  $\alpha$  by impairment of cell-cycle progression in human glioma cells. *Cancer Res* 59, 4446-4452, 1999
  43. Kasuya H, Mizuno M, Yoshida J, Nishiyama Y, Nomoto Shuji, Nakao A. Combined effects of adeno-associated virus vector and a herpes simplex virus mutant as neoplastic therapy. *J Surgical Oncology* 74, 214-218, 2000
  44. Ryuke Y, Mizuno M, Natsume A, and Yoshida J. Transduction efficiency of adenoviral vectors into human glioma cells increased by association with cationic liposomes. *Neurol Med Chir* 40, 256-260, 2000
  45. Natsume A, Tsujimura K, Mizuno M, Takahashi T, and Yoshida J. IFN- $\beta$  gene therapy induces systemic antitumor immunity against malignant glioma. *J Neuro-Oncology* 47, 117-124, 2000
  46. Natsume A, Mizuno M, Ryuke Y, and Yoshida J. Cationic liposome conjugation to recombinant adenoviral vector reduces viral antigenicity. *Jpn J Cancer Res* 91, 363-367, 2000
  47. Hatano N, Wakabayashi T, Kajita Y, Mizuno M, Ohno T, Nakayashiki N, Takemura A, Yoshida J. Efficacy of post operative adjuvant therapy with human interferon beta, MCNU and radiation (IMR) for malignant glioma: Comparison among three protocol. *Acta Neurochirurgica* 142, 633-639, 2000
  48. Nakayashiki N, Yoshikawa K, Nakamura K, Hanai N, Okamoto K, Okamoto S, Mizuno M, Wakabayashi T, Saga S, Yoshida J, and Takahashi T. Production of a single chain variable fragment antibody recognizing type III mutant epidermal growth factor receptor. *Jpn J Cancer Res* 91, 1035-1043, 2000
  49. Wakabayashi T, Hatano N, Kajita Y, Yoshida T, Mizuno M, Taniguchi K, Ohno T, Nagasaka T, Yoshida J. Initial and maintenance combined therapy treatment with interferon- $\beta$ , MCNU (Ranimustine), and radiotherapy for patients with previously untreated malignant glioma. *J Neuro-Oncol* 49, 57-62, 2000
  50. Fukui T, Hayashi Y, Fukuhara H, Yamamoto N, Nishikawa M, Mitsudo K, Tohnai I, Ueda M, Mizuno M, Yoshida J. Suicide gene therapy for human oral squamous cell carcinoma with adeno-associated virus vector. *Oral Oncol* 7, 187-189, 2001
  51. Yamamoto N, Hayashi Y, Fukuhara H, Fukui T, Nishikawa M, Mitsudo K, Tohnai I, Ueda

M, Mizuno M, Yoshida J. Basic research on interferon gene therapy for oral squamous cell carcinoma. *Oral Oncol* 7, 492-494, 2001

52. Nishikawa M, Hayashi Y, Yamamoto N, Fukui T, Fukuhara H, Mitsudo K, Tohnai I, Ueda M, Mizuno M, Yoshida J. Cell death of human oral squamous cell carcinoma cell line induced by herpes simplex virus thymidine kinase gene and ganciclovir. *Oral Oncol* 7, 578-580, 2001

53. Kageshita T, Mizuno M, Ono T, Matsumoto K, Saida T, Yoshida J. Growth inhibition of human malignant melanoma transfected with the human interferon- $\beta$  gene by means of cationic liposomes. *Melanoma Res* 11, 337-342, 2001

54. Yoshida T, Mizuno M, Taniguchi K, Nakayashiki N, Wakabayashi T, Yoshida J. Rat glioma cell death induced by cationic liposome-mediated transfer for the herpes simplex virus thymidine kinase gene followed by ganciclovir treatment. *J Surgcal Oncol* 76: 19-25, 2001

55. Wakabayashi T, Kajita Y, Mizuno M, Nagasaka T, Yoshida J. Efficacy of adjuvant therapy with procarbazine, MCNU and vincristine for oligodendroglial tumors. *Neurologia Medico-Chirurgica* 41, 115-120, 2001

56. Aoki H, Mizuno M, Natsume A, Tsugawa T, Tsujimura K, Takahashi T, Yoshida J. Dendritic cells pulsed with tumor extract-cationic liposomes complex increase the induction of cytotoxic T lymphocytes in mouse brain tumor. *Cancer Immunol Immunother* 50, 463-468, 2001

57. Okamoto K, Mizuno M, Nakahara N, Natsume A, Yoshida J, Mori T, Hori S, Kobayashi H. Process of apoptosis induced by TNF- $\alpha$  in murine fibroblast Ltk- cell: Continuous observation with video enhanced contrast microscopy. *Apoptosis* 7, 77-86, 2002

⑧影下登志郎 熊本大学医学部皮膚科学講座助教授

1. Abe S, Ono T, Kageshita T. Bathtub burn. *J Dermatol* 7, 351-356, 1980

2. Ono T, Johno M, Kito M, Tomoda T, Kageshita T, Egawa K. Evaluation of tonsillectomy as a treatment for pustulosis palmaris et plantaris. *Acta Otolaryngol Suppl* 401, 12-16, 1983

3. Ono T, Johno M, Kageshita T. Morphological and immunological studies on pustulosis palmaris et plantaris, especially on its focal theory. *Acta Otolaryngol Suppl* 401, 17-21, 1983

4. Miike T, Ohtani Y, Hattori S, Ono T, Kageshita T, Matsuda I. Childhood-type myositis and linear scleroderma. *Neurology* 33, 928-930, 1983

5. Maekawa Y, Kageshita T, Nagata T. A case of acute febrile neutrophilic dermatitis- a demonstration of IgM and C3 deposition on the vessel walls in involved skin. *J Dermatol* 11, 560-564, 1984

6. Kageshita T, Johno M, Ono T, Arao T, Imai K. Immunohistological detection of human malignant melanoma using monoclonal antibody to a melanoma-associated antigen. *Arch Dermatol Res* 277, 334-336, 1985

7. Kageshita T, Johno M, Ono T, Arao T, Imai K. Immunohistochemical analysis of antimelanoma monoclonal antibodies, with special references to fetal tissue distribution. *J Invest Dermatol* 85, 535-537, 1985

8. Ono T, Kageshita T, Nagano H. Lamina externa of the dermal melanin producing cells. *Basement Membrane*(Shibata S. ed.) Elsevier Science Publication p457-458, 1985.

9. Kageshita T, Nagano H, Johno M, Ono T, Arao T, Imai K. Immunohistochemical study of HLA antigens and lymphocyte infiltration in melanocytic tumors. *J Dermatol* 13, 179-184, 1986
10. Kusama M, Kageshita T, Tsujisaki M, Perosa F, Ferrone S. Syngeneic antiidiotypic antisera to murine anti human high-molecular-weight melanoma associated antigen monoclonal antibodies. *Cancer Res* 47, 4312-4317, 1987
11. Ferrone S, Kageshita T. Human high molecular weight-melanoma associated antigen as a target for active specific immunotherapy. *J Dermatol* 15, 457-465, 1988
12. Kageshita T, Chen ZJ, Kim JW, Kusama M, Kekish UM, Trujillo T, Temponi M, Mittelman A, Ferrone S. Murine antiidiotypic monoclonal antibodies to syngeneic antihuman high molecular weight-melanoma associated antigen monoclonal antibodies. Development, characterization and clinical applications. *Pigment Cell Res. Supple* 1, 185-191, 1988
13. Kageshita T, Temponi M, Kekish UM, Chen ZJ, Kim JW, Mittelman A, Ferrone S. Human high molecular weight-melanoma associated antigen as a target for active specific immunotherapy. A phase 1 clinical trial with murine antiidiotypic monoclonal antibodies. *Molecular Probes: Technology and Medical Application*. (Albertini A et al eds.) Raven Press, New York, p245-260, 1989
14. Perosa F, Kageshita T, Ono R, Ferrone S. Comparison of serological method to detect antiidiotypic antibodies. *Methods in Enzymology* (eds. Langma) Academic Press, New York, 178, 74-90, 1989
15. Natali PG, Fawwaz R, Ruitter DJ, Kageshita T, Temponi M, Ferrone S. Immunodiagnostic and immunotherapeutic applications of anti human melanoma associated antigen monoclonal antibodies. *Skin Tumor, Experimental and Clinical Aspects*. (Claudio J. Conti eds.) Raven Press, New York. p133-136, 1989
16. Kageshita T, Arao T. Malignant melanoma and nevus cell nevus. *A Color Atlas of Dermato-Immunohistocytology*. (Ueki H, Yaoita H. eds.) Wolfe Medical Publications, London, p128-130, 1989
17. Kusama M, Kageshita T, Chen ZJ, Ferrone S. Idiotypic analysis of murine anti human HMW-MAA monoclonal antibodies. Production and characterization of syngeneic antiidiotypic monoclonal antibodies. *J Immunol* 143, 3844-3852, 1989
18. Temponi M, Kageshita T, Perosa F, Ono R, Okada H, Ferrone S. Purification of murine IgG monoclonal antibodies by precipitation with caprylic acid. Comparison with other methods of purification. *Hybridoma* 8, 85-96, 1989
19. Arao T, Yamada M, Matsunaga W, Kageshita T, Ono T. A case of proliferating giant pigmented nevus. *J Invest Dermatol.* 92S, 315S-317S, 1989
20. Kageshita T, Temponi M, Kekish UM, Chen ZJ, Mittelman A, Matsui M, Ferrone S. Active specific and passive immunotherapy of melanoma. Clinical and experimenal investigations with murine monoclonal antibodies. *Malignant melanoma. From basic research to clinical application*. (Ferrone S. eds.) Springer-Verlag, Berlin, p475-496, 1990
21. Chen ZJ, Yang H, Yamada M, Kageshita T, Zheng Y, Bae JW, Mittelman A, Ferrone S. Murine antiidiotypic monoclonal antibodies which bear the mirror image of human high

molecular weight-melanoma associated antigen. In Cellular immunity and the immunotherapy of cancer, UCLA symposia on molecular and Cellular biology. (Lotze MJ. eds.) Wilry-Liss, New York, NY. 135, 351-359, 1990

22. Mittelman A, Chen ZJ, Kageshita T, Yang H, Yamada M, Baskind P, Goldberg N, Puccio C, Ahmed T, Arlin T, Ferrone S. Active specific immunotherapy in patients with melanoma. Clinical trial with mouse antiidiotypic monoclonal antibodies elicited with syngeneic anti HMW-MAA monoclonal antibodies. *J Clin Invest* 86, 2136-2144, 1990

23. Kageshita T, Nakamura T, Yamada M, Kuriya N, Arao T, Ferrone S. Differential expression of melanoma associated antigens in acral lentiginous melanoma and in nodular melanoma. *Cancer Res* 51, 1726-1732, 1991.

24. Ono T, Kageshita T, Hirai S, Kayashima K, Ishimaru Y. Coexistence of spherulocytic disease (Myelospherosis) and membranocystic degeneration. *Arch Dermatol* 127, 88-90, 1991

25. Zhao J, Yoshioka K, Miike T, Kageshita T, Arao T. Nerve growth factor receptor immunoreactivity on the tunica adventitia of intramuscular blood vessels in childhood muscular dystrophies *Neuromuscular Disorders* 1, 135-141, 1991

26. Chen ZJ, Yang H, Kageshita T, Ferrone S. Human high molecular weight-melanoma associated antigen (HMW-MAA) mimicry by mouse antiidiotypic monoclonal antibody TK7-371. *Cancer Res* 51, 4790-4797, 1991

27. Kageshita T, Arao T. Malignes Melanoma und Navuszellnavi In *Dermato-Immunhistochemie Atlas und Hand buch fur Klinik und Praxis*. (Laaff, Wiemers, Ueki, Yaoita eds.) Wissenschaftliche Verlagsgesellschaft mbH Stuttgart, Germany. 1991 p177-181

28. Kageshita T, Ono T, Hirai S, Yoshii A, Kimura T, Nakakuma H, Horikawa K, Takatsuki K, Ferrone S. Ganglioside, adhesion molecule and HLA antigen expression in basal cell carcinoma lesions. *Cancer Res.* 52, 3201-3207, 1992

29. Kageshita T, Yamada M, Arao T, Ferrone S. Expression of high molecular weight-melanoma associated antigen (HMW-MAA) in primary ALM lesion is associated with a poor prognosis. *Pigment Cell Res Suppl* 2, 132-135, 1992

30. Nakakuma H, Horikawa K, Kawaguchi T, Hidaka M, Nagakura S, Hirai S, Kageshita T, Ono T, Kagimoto T, Iwamori M, Takatsuki K. Common phenotypic expression of gangliosides GM3 and GD3 in normal human tissues and neoplastic skin lesions. *Jap J Clini Oncology* 22, 308-312, 1992

31. Inaba Y, Egawa K, Kageshita T, Ono T. Expression of CA50 in normal human skin: comparative study of CEA and CA19-9. *J Dermatol* 19, 592-597, 1992

32. Fujiwara S, Shinkai H, Takayasu S, Owaribe K, Tsukita S, Kageshita T. A case of subepidermal blister disease associated with autoantibody against 450 kD protein. *J Dermatol* 19, 610-613, 1992

33. Kageshita T, Yoshii A, Kimura T, Ono T. Analysis of expression and soluble form of intercellular adhesion molecule-1 in malignant melanoma. *J Dermatol* 19, 836-840, 1992

34. Kageshita T, Kuriya N, Ono T, Horikoshi T, Takahashi M, Wong GY, Ferrone S. Association of high molecular weight-melanoma associated antigen expression in primary acral

lentiginous melanoma lesions with poor prognosis. *Cancer Res* 53, 2830-2833, 1993

35. Kageshita T, Wang Z, Calorini L, Yoshii A, Kimura T, Ono T, Gattoni-Celli S, Ferrone S. Selective loss of human leukocyte Class I allospecificities and staining of melanoma cells by monoclonal antibodies recognizing monomorphic determinants of Class I human leukocyte antigens. *Cancer Res* 53, 3349-3354, 1993

36. Kageshita T, Yoshii A, Kimura T, Kuriya N, Ono T, Tsujizaki M, Imai K, Ferrone S. Clinical relevance of ICAM-1 expression in primary lesions and serum of patients with malignant melanoma. *Cancer Res* 53, 4927-4932, 1993

37. Ferrone S, Chen ZJ, Liu C, Hirai S, Chen C, Kageshita T, Mittelman A. Human high molecular weight-melanoma associated antigen mimicry by mouse anti-idiotypic monoclonal antibodies MK2-23. Experimental studies and clinical trials in patients with malignant melanoma. *Pharmac Ther* 57, 259-290, 1993

38. Yang H, Chen ZJ, Kageshita T, Yamada M, Ferrone S. Idiotypic cascade in the human high molecular weight-melanoma associated antigen system: fine specificity and idiotypic profile of anti-anti-idiotypic monoclonal antibodies. *Eur J Immunol* 23, 1671-1677, 1993

39. Ferrone S, Kageshita T, Hirai S. Active specific immunotherapy of malignant melanoma with anti-idiotypic monoclonal antibodies. *J Dermatol* 20, 533-539, 1993.

40. Kageshita T, Kimura T, Yoshii A, Hirai S, Ono T, Ferrone S. Antigenic profile of mucous melanoma lesions. *Int J Cancer* 56, 370-374, 1994

41. Kageshita T, Yoshii A, Kimura T, Maruo K, Ono T, Himeno M, Nishimura Y. Biochemical and immunohistochemical analysis of cathepsin B, H, L and D in human melanocytic tumors. *Arch Dermatol Res* 287, 266-272, 1995

42. Yoshii A, Kageshita T, Tsushima H, Ono T. Clinical relevance of cathepsin B-like enzyme activity and cysteine proteinase inhibitor in melanocytic tumors. *Arch Dermatol Res* 287, 209-213, 1995

43. Kageshita T, Hirai S, Ono T, Ferrone S. Human high molecular weight-melanoma associated antigen mimicry by mouse anti-idiotypic mAb MK2-23. Immunohistochemical analysis of the reactivity of anti-anti-idiotypic mAb with surgically removed melanoma lesions. *Int J Cancer* 60, 334-340, 1995

44. Kageshita T, Hirai S, Kimura T, Hanai S, Ohta S, Ono T. Association between sialyl-Lewis<sup>x</sup> expression and tumor progression in melanoma. *Cancer Res* 55, 1748-1751, 1995

45. Ikeda I, Kageshita T, Ono T. Multiple malignant melanoma and squamous cell carcinoma in a burn scar. *Dermatology* 191, 328-332, 1995

46. Kageshita T, Ono T, Himeno M, Nishimura Y. Biochemical and immunohistochemical analysis of cathepsins B, H, L and D in human melanocytic tumors. *Proteases Involved in Cancer* (Suzuki M. and Hiwasa T. eds.). Monduzzi Editore, Italy, p65-69, 1995

47. Ye Z, Kageshita T, Ishihara H, Ito S, Ono T. A case of malignant melanoma- Disease progression correlated with serum 5-S-CD and ICAM-1. *J Dermatol* 22, 370-375, 1995

48. Hicklin D., Kageshita T., Ferrone S. Development and characterization of rabbit antisera to human MHC-linked transporters associated with antigen processing. *Tissue Antigens* 48, 38-46,

1996

49. Hirai S., Kageshita T., Kimura T., Tsujisaki M., Okajima K., Imai K., Ono T. Soluble intercellular adhesion molecule-1 (sICAM-1) and sE-selectin levels in patients with atopic dermatitis. *Br J Dermatol* 134, 657-661, 1996
50. Kageshita T., Hirai S., Hanai N., Ohta S., Ono T. Expression of sialyl-Lewisa in malignant melanoma correlates with the depth of tumor invasion and metastasis. *Immunology of Human Melanom.* (eds. Maio M.) IOS press, Washington, DC. p39-46, 1996
51. Hamby CV, Kageshita T, Wang Z, Liang B, Temponi M, Ferrone S. Analysis of alpha v/beta 3 integrin expression by cultured human melanoma cells. *Melanogenesis and Malignant Melanoma: Biochemistry, Cell Biology, Pathophysiology, Diagnosis and Treatment.*(eds. Hori Y, Hearing VJ, Nakayama J.) Elsevier, Amsterdam. p185- 193, 1996
52. Hicklin DJ, Kageshita T, Dellaratta DV, Boccaletti V, Ferrone S. Defects in HLA Class I antigen presentation machinery in melanoma cells. *Immunology of Human Melanoma.*(ed. Maio M.) IOS press, Washington, DC. p95-111, 1996
53. Nakayama J, Kageshita T, Nakashima M, Tsujisaki M, Imai K, Hori Y. Increase in shedding of intercellular adhesion molecule-1 in human malignant melanoma cell lines treated with hyperthermia in vitro. *Pigment Cell Res* 9, 154-158, 1996
54. Kageshita T, Hirai S, Ono T, Ferrone S. Comparison of the reactivity of frozen and formalin-fixed, paraffin-embedded sections of melanoma lesions with anti-HLA Class I mAb. *HLA: Genetic diversity of HLA functional and medical implication. Volume II* (ed. Charron D.) EDK, Paris. p737-739, 1997
55. Hicklin DJ, Kageshita T, Dellaratta D, Ferrone S. Transporter associated with antigen processing (TAP) downregulation in human melanoma cells. *HLA: Genetic diversity of HLA functional and medical implication. Volume II* (ed. Charron D.) EDK, Paris. p742-744, 1997
56. Garrido F, Cabera T, Accolla RS, Bensa JC, Bodmer W, Dohr G, Drouer M, Faucher R, Ferrara GB, Ferrone S, Giacomini P, Kageshita T, Koopman L, Maio M, Marincola F, Mazzilli C, Morel PA, Murray A, Papasteriades CRH, Salvaneschi L, Stern PL, Ziegler A. HLA and cancer: 12th International Histocompatibility Workshop study. *HLA: Genetic diversity of HLA functional and medical implication. Volume I* (ed. Charron D.) EDK, Paris. p445-452, 1997
57. Kageshita T, Naruse T, Hirai S, Horikoshi T, Nakagawa H, Tamaki K, Hayashibe K, Ichihashi M, Nakayama J, Hori Y, Ozawa A, Miyahara M, Ohkido M, Inoko H, Ono T. HLA class I antigens in Japanese patients with melanoma. *J Immunother* 19, 428-432, 1997
58. Kageshita T, Naruse T, Hirai S, Ono T, Horikoshi T, Nakagawa H, Tamaki K, Hayashibe K, Ichihashi M, Nakayama J, Hori Y, Ozawa A, Miyahara M, Ohkido M, Inoko H. Molecular genetic analysis of HLA class II alleles in Japanese patients with melanoma. *Tissue Antigens* 49, 466-470, 1997
59. Hirai S, Kageshita T, Kimura T, Tsujisaki M, Imai K, Wakamatsu K, Ito S, Ono T. Serum levels of sICAM-1 and S-S-Cysteinyl-dopa as markers of melanoma progression. *Melanoma Res* 7, 58-62, 1997

60. Hicklin DJ, Dellaratta DV, Kishore R, Liang B, Kageshita T, Ferrone S. Beta 2-microglobulin gene mutations in human melanoma cells: Molecular characterization and implications for immune surveillance. *Melanoma Res* 7(Suppl 2), S67-S74, 1997
61. Kageshita T, Kawakami Y, Hirai S, Ono T. Differential expression of MART-1 in primary and metastatic melanoma lesions. *J Immunother* 20, 460-465, 1997
62. Dellaratta D, Hicklin DJ, Kishore R, Kageshita T, Ferrone S. Characterization of rabbit antisera elicited with human LMP2- and LMP7-specific peptides and recombinant proteins. *Tissue Antigens* 50, 567-575, 1997
63. Kishore R, Hicklin DJ, Dellaratta DV, Golde U, Kageshita T, Seliger B, Ferrone S. Development and characterization of mouse anti-human LMP2, LMP7, TAP1 and TAP2 monoclonal antibodies. *Tissue Antigens* 51, 129-140, 1998
64. Desai SA, Wang X, Noronha EJ, Kageshita T, Ferrone S. Characterization of human anti-high molecular weight-melanoma associated antigen single chain Fv antibodies isolated from a phage display antibody library. *Cancer Res* 58, 2417-2425, 1998
65. Matsui T, Kageshita T, Ishihara T, Tomiguchi S, Takahashi M, Ono T. Hypercalcemia in malignant melanoma arising in congenital giant pigmented nevus - a case showing increasing serum level of parathyroid hormone-related protein (PTHrP). *Dermatology* 197, 65-68, 1998
66. Noronha EJ, Wang X, Desai SA, Kageshita T, Ferrone S. Limited diversity of human scFv fragments isolated by panning a synthetic phage display scFv library with cultured human melanoma cells. *J Immunol* 161, 2968-2976, 1998
67. Hirai S, Shin Y, Kageshita T, Syono M, Maekawa Y, Ono T. Clinical course of atopic dermatitis in Japanese patients. *J Dermatol Sci* 18, 128-131, 1998
68. Suenaga Y, Katabuchi H, Okamura H, Kageshita T, Ono T. Increased serum levels of 5-S-Cysteinyl-dopa and intercellular adhesion molecule-1 in a patient with a uterine amelanotic metastasis from a primary vaginal malignant melanoma. *Gynecologic Oncology* 72, 107-110, 1999
69. Kageshita T, Hirai S, Ono T, Hicklin DJ, Ferrone S. Downregulation of HLA class I antigens processing molecules in malignant melanoma. Association with disease progression. *Am J Pathol* 154, 745-754, 1999
70. Kageshita T, Yamamoto A, Yamazaki N, Ishihara K, Ono T. Low frequency of neutralizing antibodies against natural interferon- $\beta$  during adjuvant therapy for Japanese patients with melanoma. *J Dermatol Sci* 19, 208-212, 1999
71. Kageshita T, Matsui T, Hirai S, Fukuda Y, Ono T. Hypercalcemia in melanoma patients associated with increased levels of parathyroid hormone related protein. *Melanoma Res* 9, 69-73, 1999
72. Tomoda A, Miike T, Iwatani N, Ninomiya T, Mabe H, Kageshita T, Ito S. Effect of long-term melatonin administration on school-phobic children and adolescents with sleep disturbances. *Curr Ther Res Clin E* 60, 607-612, 1999
73. Kageshita T, Hamby CV, Hirai S, Kimura T, Ono T, Ferrone S. Differential clinical significance of  $\alpha$  v  $\beta$  3 expression in primary lesions of acral lentiginous



- melanoma and in primary lesions of other melanoma histotypes. *Int J Cancer* 89, 153-159, 2000
74. Kageshita T, Kuribayashi N, Ono T. Myelodysplastic syndrome following treatment of malignant melanoma with vincristine, ACNU, dacarbazine. *J Dermatol* 27, 178-180, 2000
75. Kageshita T, Hamby CV, Hirai S, Kimura T, Ono T, Ferrone S.  $\alpha v \beta 3$  expression on blood vessels and tumor cells in primary melanoma lesions; differential association with tumor progression and clinical prognosis. *Cancer Immunol Immunother* 49, 314-318, 2000
76. Kageshita T, Kawakami Y, Ono T. Clinical significance of MART-1 and HLA-A2 expression and CD8+ T cell infiltration in melanocytic lesions in HLA-A2 phenotype patients. *J Dermatol Sci* 25, 36-44, 2001
77. Kageshita T, Mizuno M, Ono T, Matsumoto K, Saida T, Yoshida J. Growth inhibition of human malignant melanoma transfected with the human interferon- $\beta$  gene by means of cationic liposomes. *Melanoma Res* 11, 337-342, 2001
78. Kageshita T, Funasaka Y, Ichihashi M, Wakamatsu K, Ito S, Ono T. Tissue factor expression and serum level in patients with melanoma does not correlate with disease progression. *Pigment Cell Res* 14, 195-200, 2001
79. Wakasugi S, Kageshita T, Ono T. Metastatic melanoma to the palatine tonsil with a favorable prognosis. *Br J Dermatol* 145, 327-329, 2001
80. Kageshita T, Hamby CV, Ishihara T, Matsumoto K, Saida T, Ono T. Loss of  $\beta$ -catenin expression was associated with disease progression in malignant melanoma. *Br J Dermatol* 145, 210-216, 2001
81. Ishihara T, Nakamura A, Kageshita T, Ono T. Sentinel lymph nodes study in 30 cases of melanoma. *J Dermatol* 28, 347-352, 2001
82. Katabuchi H, Honda R, Tajima T, Ohtake H, Kageshita T, Ono T, Okamura H. Clear cell sarcoma arising in the retroperitoneum. *Int J Gynecol Cancer* (in press)
83. Wakamatsu K, Kageshita T, Furue M, Hatta Y, Kiyohara Y, Nakayama J, Ono T, Saida T, Takata T, Tsuchida T, Uhara H, Yamamoto A, Yamazaki N, Naito A, Ito S. Evaluation of 5-S-cysteinyl-dopa as a marker of melanoma progression: 10 years' experience. *Melanoma Res* 12, 245-253, 2002

#### 14. その他必要な事項

##### (1)文献

- 1) Johnson TM, Smith JW, Nelson BR, et al.: Current therapy for cutaneous melanoma. *J Am Acad Dermatol* 32, 689-707, 1995
- 2) 石原和之、齋田俊明、山本明史：悪性黒色腫の発生数に関する全国アンケート（1992-1998年）. *Skin Cancer* 15, 7-14, 2000
- 3) Ishihara K, Saida T, Yamamoto A.: Updated statistical data for malignant melanoma in Japan. *Int J Clin Oncol* 6, 109-116, 2001
- 4) 石原和之、齋田俊明、山本明史：悪性黒色腫（1987-91年）の統計調査による疫学、予後因子、10年生存率. *Skin Cancer* 15, 99-107, 2000
- 5) 齋田俊明、山本明史（編）：悪性黒色腫の診断・治療指針. 金原出版、東京、2001
- 6) 齋田俊明：メラノーマの診断・治療の最新情報. *日皮会誌* 110, 1276-1275, 2000
- 7) Garbe C: Chemotherapy and chemoimmunotherapy in disseminated malignant melanoma. *Melanoma Res* 3, 291-299, 1993
- 8) 齋田俊明、宇原 久：悪性黒色腫に対する抗がん剤の適正使用ガイドライン（試案）. *Skin Cancer* 16, 158-169, 2001
- 9) Khayat D, Coeffic D: Chemotherapy and chemoimmunotherapy for metastatic malignant melanoma: Review and recent advances. *Jpn J Cancer Chemother* 27, 238-247, 2000
- 10) Nestle FO, Alijagic S, Gilliet M, et al.: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. *Nat Med* 4, 328-332, 1998
- 11) Yagi K, Noda H, Kurono M, et al.: Efficient gene transfer with less cytotoxicity by means of cationic multilamellar liposomes. *Biochem Biophys Res Commun* 196, 1042-1048, 1993
- 12) Yoshida J, Mizuno M, Yagi K: Cytotoxicity of human  $\beta$ -interferon produced by human glioma cells transfected with its gene by means of liposomes. *Biochem Int* 28, 1055-1061, 1992
- 13) Horikoshi T, Fukazawa K, Hanada N, et al.: In vitro comparative study of the antitumor effects of human interferon- $\alpha$ ,  $\beta$  and  $\gamma$  on the growth and invasive potential of human melanoma cells. *J Dermatol* 22, 631-636, 1995
- 14) Nagatani T, Okazawa H, Kambara T, et al.: Effect of natural interferon- $\beta$  on the growth of melanoma cell lines. *Melanoma Res* 8, 295-299, 1998
- 15) Castello G, Ruoclo V, Satriano RA, et al.: Role of interferons in the therapy of melanoma. *Melanoma Res* 1, 311-325, 1991
- 16) Chawla-Sarkar M, Leaman DW, Borden EC. Preferential induction of apoptosis by interferon- $\beta$  compared with interferon- $\alpha$  2: correlation with trail/apo21 induction in melanoma cell lines. *Clin Cancer Res* 7, 1821-1831, 2001
- 17) Ishihara K, Hayasaka K, Yamazaki N: Current status of melanoma treatment with interferon, cytokines and other biologic response modifiers in Japan. *J Invest Dermatol* 92, 326S-328S, 1989
- 18) Saida T: Recent advances in melanoma research. *J Dermatol Sci* 26, 1-13, 2001
- 19) Hanson C, Kopf I, Weijdegard B, et al.: Sensitivity to extrinsically supplied interferon in melanoma cell lines. *Melanoma Res* 9, 451-456, 1999

- 20) Taniguchi T, Takaoka A: A weak signal for strong responses: Interferon- $\alpha/\beta$  revisited. *Nat Rev Mol Cell Biol* 2, 378-386, 2001
- 21) Natsume A, Mizuno M, Ryuke Y, Yoshida J: Antitumor effect and cellular immunity activation by murine interferon- $\beta$  gene transfer against intracerebral glioma in mouse. *Gene Ther* 6, 1626-1633, 1999
- 22) Kageshita T, Mizuno M, Ono T, Matsumoto K, Saida T, Yoshida J: Growth inhibition of human malignant melanoma transfected with the human interferon- $\beta$  by means of cationic liposomes. *Melanoma Res* 11, 337-342, 2001
- 23) Taniguchi T, Ohno S, Fujii-Kuriyama K, et al.: The nucleotide sequence of human fibroblast interferon cDNA. *Gene* 10, 11-15, 1980
- 24) Kopf J, Hanson C, Delle U, et al.: Action of interferon  $\alpha$  and  $\beta$  on four human melanoma cell lines in vitro. *Anticancer Res* 16, 791-804, 1996
- 25) 橋爪鈴男：ヌードマウス可移植性ヒト悪性黒色腫に対するヒトインターフェロンの抗腫瘍効果. *Skin Cancer* 1, 41-46, 1986
- 26) 石原和之：Human fibroblast interferon (Hu IFN- $\beta$ ) による皮膚悪性腫瘍に対する臨床的研究. *日本癌治学会誌* 18, 41-53, 1983
- 27) Fountain JW, karayiorgon M, Ernstoff MS, et al.: homozygous deletions within human chromosome 9p21 in melanoma. *Proc Natl Acad Sci USA* 89, 10557-10561, 1992
- 28) Qin XQ, Tao N, Dergay A, et al.: Interferon- $\beta$  gene therapy inhibits tumor formation and causes regression of established tumors in immune-deficient mice. *Proc Natl Acad Sci USA* 95, 14411-14416, 1998
- 29) 阿部博子、小西啓悦、八木國夫：プラスミド封入りポソームの細胞内取り込みに関する形態学的検索. 厚生省新薬開発研究, 医薬品担体応用リポソームの開発研班平成元年度研究報告書, p.13-18, 1993
- 30) 鬼頭万里子、大石誠子、八木國夫：M 期同調細胞における遺伝子移入. *蛋白質核酸酵素* 36, 2242-245 1991
- 31) Natsume A, Tsujimoto K, Mizuno M, Takahashi T, Yoshida J: IFN- $\beta$  gene therapy induces systemic antitumor immunity against malignant glioma. *J Neuro-Oncol* 47 117-124, 2000
- 32) Xie K, Bielenberg D, Huang S, Xu L, Salas T, Juang SH, Dong Z, Fidler IJ. Abrogation of tumorigenicity and metastasis of murine and human tumor cells by transfection with the murine IFN- $\beta$  gene: Possible role of nitric oxide. *Clin Cancer Res* 3, 2283-2294, 1997
- 33) Rosenberg SA: Gene therapy for cancer. *JAMA* 268, 2416-2419, 1992
- 34) Nabel GJ, Nabel EG, Yang Z-Y, et al.: Direct gene transfer with DNA-liposome complex in melanoma: Expression, biologic activity, and lack of toxicity in humans. *Proc Natl Acad Sci USA* 90, 11307-11311, 1993
- 35) Hui KM, Ang PT, Huang L, et al.: Phase I study of immunotherapy of cutaneous metastases of human carcinoma using allogeneic and xenogeneic MHC DNA-liposome complexes. *Gene Ther* 4:783-790, 1997
- 36) Rosenberg SA, Zhai Y, Yang JC, et al.: Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. *J Natl Cancer*

Inst 90, 1894-1900, 1998

37) Palmer K, Moore J, Everard M, et al.: Gene therapy with autologous, interleukin 2-secreting tumor cells in patients with malignant melanoma. *Hum Gene Ther* 10, 1261-1268, 1999

38) Fujiti S, Huang S, Fong TC, et al.: Induction of melanoma-associated antigen systemic immunity upon intratumoral delivery of interferon- $\gamma$  retroviral vector in melanoma patients. *Cancer Gene Ther* 7, 1210-1230, 2000

39) Kang WK, Park C, Yoon HL, et al.: Interleukin 12 gene therapy of cancer by peritumoral injection of transduced autologous fibroblasts: Outcome of a phase I study. *Hum Gene Ther* 12, 671-684, 2001

40) Felgner PL, Gadek TR, Holm M, et al.: Lipofectin: A highly efficient, lipid-mediated DNA-transfection procedure. *Proc Natl Acad Sci USA* 84, 7413-7417, 1987

41) Caplen NJ, Alton EW, Middleton PG, et al.: Liposome-mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. *Nat Med* 1, 39-46, 1995

42) Goddard CA, Ratcliff R, Anderson, JR, et al.: A second dose of a CFTR cDNA-liposome complex is as effective as the first dose in restoring cAMP-dependent chloride secretion to null CF mice trachea. *Gene Ther* 4, 1231-1236, 1997